Samsung Bioepis JV with Biogen Idec moves on Remicade biosimilar in Europe

South Korea's Samsung Bioepis has submitted a marketing authorization application to the European Medicines Agency (EMA) for SB2, a biosimilar of autoimmune drug Remicade (infliximab) for moderate to severe rheumatoid arthritis.

Samsung Bioepis, a joint venture with Biogen Idec ($BIIB), has completed head-to-head studies on the original from Merck & Co. ($MRK) and Johnson & Johnson ($JNJ).

Earlier this year, South Korea's Celltrion launched its Remicade biosimilar, dubbed Remsima, in Europe.

Celltrion's co-exclusive partner, Hospira ($HSP), markets the biosimilar independently as Inflectra in Europe.

SB4, a Samsung Bioepis biosimilar of autoimmune drug Enbrel (etanercept) from Amgen ($AMGN) and Pfizer ($PFE), is also under EMA marketing authorization review.

- get more from Samsung Bioepis